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Summary  Malignant  ventricular  arrhythmias  and  sudden  cardiac  death  may  late  happen  in
repaired  tetralogy  of  Fallot,  although  probably  less  frequently  than  previously  thought,  espe-
cially with  the  advent  of  new  surgical  techniques/management.  Ventricular  tachycardias  areVentricular
tachycardia;
Sudden  death;
caused by  reentry  around  the  surgical  scars/patches  and  valves.  Many  predictive  factors  have
been proposed,  which  suffer  from  poor  accuracy.  There  is  currently  no  recommended  indication
for prophylactic  implantable  cardioverter  defibrillator  implantation—except  maybe  in  the  caseAblation of multiple  risk  factors—while  radiofrequncy  ablation  may  be  proposed  in  secondary  preven-
tion with  or  even  without  a  back-up  implantable  cardioverter  defibrillator  in  selected  cases.
Abbreviations: ACHD, adult congenital heart disease; GUCH, grown-up congenital heart disease; ICD, implantable cardioverter defibril-
ator; RVOT, right ventricular outflow tract; SCD, sudden cardiac death; TOF, tetralogy of Fallot; VT, ventricular tachycardia.
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Repeated  cardiological  investigations  and  monitoring  should  be  proposed  for  every  operated
patient.
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Résumé  Des  arythmies  ventriculaires  malignes  ou  une  mort  subite  peuvent  survenir  tardi-
vement après  correction  chirurgicale  de  tétralogie  de  Fallot,  quoique  probablement  moins
fréquemment  que  précédemment  supposé,  surtout  avec  l’avènement  de  nouvelles  techniques
chirurgicales  ou  de  prise  en  charge.  Les  tachycardies  ventriculaires  sont  dues  à  des  réentrées
autour/entre  les  cicatrices  de  ventriculotomie  ou  patchs  et  les  anneaux  valvulaires.  Un  certain
nombre de  facteurs  favorisants  ont  été  proposés  qui  souffrent  cependant  de  valeurs  prédictives
insuffisantes  pour  être  utilisés  seuls  en  pratique  clinique.  Il  n’y  a  actuellement  pas  de  recom-
mandation  pour  l’implantation  prophylactique  de  défibrillateur  en  prévention  primaire  —  sauf
peut-être  en  cas  d’association  de  facteurs  prédictifs  multiples  —  alors  que  l’ablation  percutanée
par radiofréquence  peut  être  proposée  en  prévention  secondaire  avec  ou  même  sans  défibrilla-
teur dans  certains  cas  sélectionnés.  Des  investigations  cardiaques  répétées  et  une  surveillance
au long  cours  doivent  être  effectués  chez  chaque  patient  opéré.

































Congenital  heart  disease  is  present  in  0.9%  of  living  births;
currently,  90%  of  those  affected  will  reach  adulthood
because  of  recent  progress  made  in  paediatrics,  cardiology,
surgery  and  resuscitation  [1,2].  Among  what  are  commonly
called  ‘‘grown-up  congenital  heart  diseases’’  (GUCHs)  or,
more  recently,  ‘‘adult  congenital  heart  diseases’’  (ACHDs),
tetralogy  of  Fallot  (TOF)  has  a  preponderant  place,  because
of  its  relatively  high  prevalence  (7—10%  of  all  congenital
heart  diseases;  1/3500  to  1/4300  in  the  adult  population)
[3,4],  and  because  it  is  possible  to  have  corrective  surgery,
leading  to  almost  normal  anatomy  and  physiology  in  adult-
hood.  Indeed,  very  long-term  follow-up  has  demonstrated
that  health  status  is  excellent,  with  a  mortality  rate  that  is
considered  to  be  low  (14%  mortality  for  hospital  survivors  at
40-year  follow-up,  after  surgery  performed  in  the  1970s),
even  if  it  is  still  higher  than  in  the  general  population,
mainly  because  of  heart  failure  and  ventricular  arrhythmias
[5].  Thus,  the  third  reason  for  making  TOF  one  of  the  main
GUCHs  of  concern  is  the  late  risk  of  malignant  ventricular
arrhythmias  and  sudden  cardiac  death  (SCD).
The  aim  of  this  review  is  to  highlight  the  mechanisms
of  ventricular  arrhythmias  in  TOF,  and  to  present  current
knowledge  of  secondary  and  primary  prevention  of  SCD  in
this  setting.
SCD in GUCH patients
The  occurrence  of  SCD  in  patients  with  previous  surgical
repair  of  congenital  heart  defects  is  a  tragic  event,  as  many
are  usually  considered  to  be  ‘‘cured’’  of  their  congenital
heart  disease  (even  if  this  terminology  may  be  a  bit  too




xcellent  quality  of  survival.  Some  of  these  SCDs  are
robably  linked  to  paroxysmal  high-degree  atrioventricular
lock  (e.g.  in  repaired  TOF  with  relevant  intraventricular
onduction  disturbances,  but  also  in  ventricular  septal
efect,  cushion  defect  or  congenitally  corrected  transpo-
ition  of  the  great  arteries).  Some  other  SCDs  are  caused
y  ventricular  fibrillation  induced  by  fast  ventricular  rates
uring  supraventricular  tachycardia  (e.g.  atrial  tachycardia
ith  1/1  atrioventricular  conduction  after  atrial  switch
or  transposition  of  the  great  arteries,  or  after  Fontan
rocedures  for  single  ventricle).  Other  causes  probably
nclude  haemodynamic  compromise,  embolism,  myocardial
nfarction  or  aneurism  rupture,  but  it  is  now  clear  that
ost  SCDs  (a  proportion  estimated  at  around  75%  [6])  are
econdary  to  arrhythmias,  and  among  these,  malignant
entricular  arrhythmias  have  been  documented  in  85%  of
ases  at  the  time  of  the  cardiac  arrest  [6].
Even  if  the  culprit  GUCH  for  SCD  has  changed  in  recent
ecades,  TOF  remains  one  of  the  main  GUCHs  carrying
he  risk  of  late  SCD.  In  1974,  congenital  aortic  stenosis,
isenmenger’s  syndrome,  TOF  and  hypertrophic  obstructive
ardiomyopathy  were  responsible  for  more  than  half  of  SCDs
n  children  (non-operated  defects  in  most)  [2];  whereas  TOF,
ystemic  to  pulmonary  anastomosis,  pulmonary  hyperten-
ion  caused  by  left  to  right  shunt  and  dilated  cardiomyopathy
ere  present  in  half  of  the  SCDs  in  a  report  published
0  years  later  (postoperative  in  a significant  number  of
ases)  [7]. In  1998,  Silka  et  al.  found  that  in  3600  patients
ith  GUCH,  most  late  SCDs  were  linked  to  aortic  stenosis,
ortic  coarctation,  transposition  of  the  great  arteries  and
OF,  leading  to  a  yearly  SCD  rate  of  0.22%  (50  to  200  times
igher  than  in  the  general  population);  most  were  suspected
o  have  an  arrhythmic  cause  [6].  Similar  causes  of  SCD  have
een  found  in  more  recent  studies  [8].  However,  even  if  it  is




































































































f  death  in  GUCH,  representing  only  one-quarter  of  all-cause
ortalities  in  adults  with  GUCH  in  many  series  [6,9,10],  or
ven  fewer,  according  to  more  recent  data  [11],  while  it  is
nown  to  account  for  half  of  cardiac  deaths  among  those
ith  acquired  heart  disease.
Prospective  trials  regarding  SCD  in  GUCH  are  lacking  for
any  reasons:
first,  these  are  very  heterogeneous  defects;
second,  the  number  of  cases  needed  to  reach  statisti-
cal  power  makes  any  trial  almost  unachievable  (e.g.  TOF
would  require  1700  patients  to  be  followed  for  10  years)
[12];
third,  earlier  conclusions  may  not  be  relevant  to  newer
generations  of  patients  with  GUCH  (complete  repairs
during  the  neonatal  period,  improved  physiological  out-
comes,  extended  survival  of  patients  with  more  complex
forms)  [13].
CD and ventricular arrhythmias in TOF
he  modern  management  of  TOF  began  before  the  1960s,
fter  the  first  surgical  complete  repair  performed  by  Dr
.  C.  Lillehei  in  1954.  As  early  as  1975  —  around  15  to
0  years  later  —  the  first  cases  of  unexpected  cardiac  arrest
n  repaired  TOF  were  noticed,  and  were  already  suspected
o  be  caused  by  malignant  ventricular  arrhythmias  [14—16].
Since  then,  SCD  has  been  identified  repeatedly  as  the
ajor  cause  of  mortality  in  repaired  TOF,  representing,
owever,  only  one-third  to  half  of  all-cause  mortalities  in
ifferent  series  [14,17—19].  Over  the  past  30  years,  many
tudies  have  evaluated  the  risk  of  SCD  in  TOF  to  be  between
 and  0.8%  yearly  [6,14,16—23].  In  a  meta-analysis  includ-
ng  39  studies  and  4583  patients,  the  late  rate  of  SCD  in
OF  was  evaluated  to  be  1.8%  over  more  than  8  years  of
ollow-up,  i.e.  an  annual  SCD  rate  of  only  0.15%  [21],  which
s,  of  course,  higher  than  in  the  general  population,  but
oes  not  constitute  an  objectively  ‘‘high’’  risk  sufficient
o  warrant  systematic  prevention.  For  comparison,  a  yearly
isk  of  SCD  of  up  to  0.8%  in  hypertrophic  cardiomyopathy
oes  not  constitute  an  indication  for  an  implantable  car-
ioverter  defibrillator  (ICD)  [24].  Interestingly,  the  risk  of
ate  SCD  in  TOF  is  not  linear  but  increases  over  time,  espe-
ially  20—25  years  after  the  surgery  [6,19].  However,  it  is
till  unclear  if  this  increase  is  simply  caused  by  ageing  or  is
ependent  on  ongoing  progress  in  surgical  techniques.
For  the  occurrence  of  sustained  ventricular  tachycardia
VT),  the  risk  has  been  evaluated  as  4%  at  21-year  follow-up
i.e.  0.2%  yearly)  [17],  and  as  14%  in  556  adults  operated  on
or  TOF  after  a  follow-up  of  around  30  years  [25].  The  risk
lso  changes  with  age,  with  an  increase  at  around  40  years
f  age  [25].  Thus,  it  is  tempting  and  logical  to  mainly  link
CD  in  TOF  to  the  occurrence  of  sustained  VT.
echanisms of VT and SCD in TOFata  on  unrepaired  TOF  are  scarce,  as  these  usually  have
 very  poor  prognosis  [26];  what  we  know  comes  from
ncient  studies,  where  ventricular  arrhythmias  were  com-
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For  repaired  TOF,  conduction  disturbances  are  probably
ot  a  common  cause  of  SCD  because  long-term  evolution
rom  right  bundle  branch  block  to  bi-/tri-fascicular  block
s  uncommon  [22],  and  because  postoperative  bi-fascicular
lock  (without  transient  high-degree  atrioventricular  block)
as  never  been  shown  to  lead  to  late  SCD  [18,22,29,30].  Only
ransient  complete  heart  block  that  persisted  beyond  the
hird  postoperative  day  has  been  correlated  with  the  risk  of
ate  SCD  [31].  Even  if  prolonged  QRS  duration  has  been  cor-
elated  with  SCD  [17,32],  QRS  prolongation  relates  rather
o  right  ventricular  size,  and  predicts  malignant  ventricu-
ar  arrhythmias  [32]. Moreover,  autopsies  in  patients  with
OF  who  died  from  SCD  revealed  that  the  conduction  tissues
ere  undamaged,  but  found  extensive  fibrosis  of  the  right
entricular  myocardium  at  both  the  ventriculotomy  site  and
he  septum  [33]. Ventricular  arrhythmias  such  as  prema-
ure  beats  [22,30]  and  documented  ventricular  fibrillation
30]  were  soon  suspected  to  be  involved  in  SCD  mechanisms
nd,  finally,  repeated  documentation  of  sustained  VT  during
borted  SCD  in  repaired  TOF  patients  [32]  sealed  the  causal
elationship  between  ventricular  arrhythmias  and  SCD.
After  the  first  cases  of  surgical  or  intracardiac  mapping
nd  ablation,  reentry  circuits  around  the  surgical  ventricu-
otomy  scars,  using  fibrotic  areas  of  slow  conduction,  have
een  shown  to  be  the  cause  of  sustained  VT  in  repaired  TOF
34—37].  It  is  not  known,  however,  if  ventricular  fibrillation
s  always  caused  by  degenerating  monomorphic  sustained
T.
actors associated with SCD in TOF
any  factors  have  been  proposed  to  try  to  better  define  the
isk  of  SCD  in  repaired  TOF  (Table  1).  These  factors  are  based
n  history,  clinical  features,  surface  electrocardiogram  or
ignal-averaged  electrocardiogram,  and  the  presence  of
pontaneous  or  inducible  arrhythmias  or  surgical  charac-
eristics,  but  also  on  echocardiographic  or  haemodynamic
ariables  thought  to  be  associated  with  a  poorer  progno-
is.  A  review  of  all  these  variables  can  be  found  elsewhere
12]. However,  if  the  holy  grail  of  TOF  risk  stratification  lies
n  any  of  these  variables,  it  would  surely  have  been  found
lready.  Apart  from  the  combination  of  QRS  prolongation
nd  increased  JT  dispersion,  which  has  been  associated  with
ood  positive  and  negative  predictive  values  [38],  none  of
hese  factors  has  sufficient  accuracy,  at  least  individually,  to
llow  their  use  alone  for  risk  stratification  in  primary  pre-
ention.  Moreover,  most  of  these  variables  are  probably  not
ndependent  of  each  other  [12]  and  would  be  better  used  in
ombination  (see  later).
When  trying  to  explore  risk  stratification  further,  it
eemed  to  make  sense  to  first  consider  the  presence  of  com-
lex  asymptomatic  ventricular  arrhythmias  as  one  of  the
ajor  variables  linked  to  SCD;  these  were  found  in  13%  of
atients  when  looking  at  routine  electrocardiograms,  and  in
round  half  of  patients  when  looking  at  ambulatory  recor-
ings  [15,20]. The  dramatically  lower  rate  of  premature
eats  on  routine  electrocardiograms  in  uneventful  compared
ith  sudden-death  patients,  together  with  the  lower  SCD
ate  in  patients  with  frequent  ventricular  premature  beats
uccessfully  versus  unsuccessfully/not  treated  with  antiar-
hythmic  drugs  [15],  supported  this  hypothesis.  However,
Ventricular  arrhythmias  and  sudden  death  in  tetralogy  of  Fallot  
Table  1  Factors  proposed  to  be  related  to  the  risk
of  sudden  cardiac  death  in  repaired  tetralogy  of  Fallot
(modified  from  [12]).
Atrioventricular  conduction  block
Right  bundle  branch  block  with  left  axis  deviation
Atrial  arrhythmias
Sustained  ventricular  tachycardia
Non-sustained  ventricular  arrhythmias  on  24-hour
ambulatory  monitoring
Ventricular  arrhythmias  on  exercise  testing
Right  ventricular  hypertension
Residual  ventricular  septal  defect
Right  ventricular  dilation
Residual  right  ventricular  outflow  tract  obstruction
Ventricular  hypertrophy
Size  of  ventriculotomy  scar
Diminished  right  ventricular  myocardial  blood  flow
reserve
Restrictive  right  ventricular  physiology
Size  of  ventriculotomy  scar
Diminished  right  ventricular  myocardial  blood  flow
reserve
Left  ventricular  end-diastolic  pressure
Left  ventricular  involvement
Abnormal  signal-averaged  electrocardiogram
Complex  or  multiple  operations
Transventricular  as  opposed  to  transatrial  approach  to
repair
QRS  duration  on  electrocardiogram
Older  age  at  operation


















































Coronary  artery  disease
conflicting  data  exist  on  that  point  [17],  while  symptomatic
non-sustained  VT  has  been  associated  with  a  poorer  outcome
[39].
The  logical  next  step  was  to  consider  the  role  of  inducible
ventricular  arrhythmias  in  selecting  patients  prone  to  SCD,
despite  the  fact  that  inducible  patients  may  have  excel-
lent  outcome  [20]  and  that  SCD  may  occur  in  non-inducible
patients  with  TOF  [40].  Khairy  et  al.  reported  the  prognos-
tic  value  of  programmed  ventricular  stimulation  after  TOF
repair,  as  determined  in  a  multicentre  cohort  study  includ-
ing  252  patients  investigated  from  1985  to  2002  (mean  age
16  ±  12  years)  [41].  Of  note,  two-thirds  of  these  patients
had  already  presented  with  syncope,  palpitations,  sustained
VT  or  even  cardiac  arrest.  Sustained  monomorphic  VT  was
inducible  during  standard  programmed  ventricular  stimula-
tion  in  30%  of  cases,  and  polymorphic  VT  in  5%  of  cases
(under  isoproterenol  in  a  quarter  of  cases).  After  multivari-
able  analysis,  inducible  patients  were  older,  and  presented
with  palpitations,  high-grade  ventricular  premature  beats,
previous  palliative  surgery  and  a  large  cardiothoracic  ratio.
A  quarter  of  inducible  patients  were  implanted  with  an  ICD
(and  only  a  very  few  non-inducible  patients).  Overall,  17%
of  patients  experienced  SCD  or  sustained  VT  during  the  6-
year  follow-up.  Inducibility  of  any  VT  was  significantly  linked
to  arrhythmia-free  survival  in  a  multivariable  analysis  [41].
Analyses  performed  in  patients  without  ICDs  or  in  asymp-






egative  and  positive  predictive  values  of  inducibility  of  any
T  were  considered  interesting  (98%  and  25%  respectively),
ith  a  relative  risk  of  10.4  in  asymptomatic  patients,  the
5%  confidence  intervals  were  very  large,  and  the  statistical
nalysis  could  be  considered  to  be  of  borderline  significance
P  =  0.0425).  Moreover,  a  subsequent  publication  by  the  same
roup  did  not  confirm  these  results  in  patients  with  ICD  [42]
see  later).
According  to  the  2014  guidelines  for  management  of
rrhythmias  in  GUCH  [1]  and  the  2015  European  guidelines
or  SCD  [24], programmed  ventricular  stimulation  can  be
seful  in  risk  stratification  in  adults  with  repaired  TOF  who
ave  more  than  one  risk  factor  for  SCD  (including  left  ven-
ricular  systolic  or  diastolic  dysfunction,  non-sustained  VT,
RS  duration  >  180  ms  or  extensive  right  ventricular  scar-
ing;  class  IIa  indication).  According  to  the  same  guidelines,
n  ICD  may  be  proposed  for  primary  prevention  in  selected
atients  with  TOF  in  case  of  multiple  risk  factors  (i.e.  those
entioned  above,  inducible  sustained  VT;  class  IIa  indica-
ion).  In  our  opinion  and  experience,  however,  prophylactic
CD  implantation  is  rare,  and  should  be  reserved  mainly
or  left  ventricular  alteration  and/or  very  broad  QRS  and
mpaired  right  ventricular  function.
edications for ventricular arrhythmias in
OF
here  has  been  no  dedicated  study  of  antiarrhythmic  drugs
n  TOF  or,  more  generally,  in  GUCH.  Drug  management  in
UCH  is  adapted  from  what  has  been  largely  demonstrated
n  acquired  heart  disease.  Beta-blockers  are  probably  use-
ul,  while  sotalol  and  amiodarone  should  be  avoided  —  at
east  as  first-intention  treatment  —  because  of  the  risk  of
roarrhythmia  and  relevant  non-cardiological  side  effects
uring  long-term  therapy  [1].  Class  I  antiarrhythmic  drugs
ay  be  harmful  in  case  of  diseased  ventricle  [1],  as  is
resent  in  TOF.
CDs in TOF
UCH  and  children  represent  fewer  than  1%  of  all  ICD
mplantations.  Series  are  few,  and  are  usually  limited  to  tens
f  patients,  and,  of  course,  there  have  been  no  randomized
rials.  ICDs  in  GUCH  are  hampered  by  an  important  rate  of
nappropriate  therapy,  late  technical  or  psychological  issues
r  complications  with  residual  significant  mortality  rates  and
ven  relevant  SCD  rates  [43].
Patients  with  TOF  form  by  far  the  largest  subgroup
f  ICD  recipients  with  congenital  heart  disease  [44—46].
n  secondary  prevention,  an  older  report  on  25  operated
atients  with  TOF  revealed  45%  oversensing,  20%  appropri-
te  antitachycardia  pacing,  5%  appropriate  ICD  shock,  20%
nappropriate  antitachycardia  pacing,  20%  inappropriate  ICD
hock  and  5%  mortality  over  2  years  [47].
In  2008,  Khairy  et  al.  reported  their  experience  of  ICDs
n  121  implanted  patients  with  TOF,  half  of  whom  were
mplanted  for  primary  prevention  (although  a  large  number
ad  symptoms  compatible  with  ventricular  arrhythmia)  [42].
hirty  per  cent  of  patients  experienced  appropriate  therapy







































































ndependent  predictor  was  previous  ventriculotomy  inci-
ion.  One-quarter  of  patients  presented  with  inappropriate
herapy  —  either  in  primary  or  secondary  prevention  —  and
CD-related  complications  occurred  in  30%.  Interestingly,  the
ll-cause  mortality  rate  was  high  (2%  yearly,  rather  higher
han  for  unselected  TOF),  and  half  of  the  deaths  were
udden,  despite  the  ICD  [42].  In  the  subgroup  of  patients
mplanted  for  primary  prevention,  appropriate  shocks  hap-
ened  in  23%,  and  independent  predictors  were  elevated  left
entricular  end-diastolic  pressure  and  the  presence  of  non-
ustained  VT.  Interestingly,  inducibility  was  not  significantly
inked  to  the  occurrence  of  appropriate  shock.  The  authors
uilt  a  risk  score  for  predicting  appropriate  ICD  shock  in  pri-
ary  prevention,  but  other  authors  failed  to  validate  it  in
 subsequent  series  of  36  patients  with  TOF  also  implanted
or  primary  prevention  [39].  In  this  work,  only  symptomatic
on-sustained  VT  was  associated  with  future  appropriate
herapy  in  a  univariate  analysis  (which,  in  fact,  challenges
he  notion  that  these  were  really  ‘‘primary  prevention’’  TOF
atients).  In  this  report,  there  was  19%  appropriate  therapy,
2%  inappropriate  therapy  and  5%  mortality  over  the  5-year
ollow-up  [39].  However,  it  is  not  clear  if  fast  VT  prompting
CD  therapy  was  non-sustained  when  different  ICD  settings
ere  programmed.
In  a  recent  French  retrospective  registry  of  62  implanted
atients  with  TOF  (18%  in  primary  prevention),  9%  received
ppropriate  therapy  in  primary  prevention  compared  with
0%  in  secondary  prevention,  while  34%  experienced  major
CD-related  complications,  and  10%  died  over  a  follow-up
f  3.5  years  (Bouzeman,  unpublished  data).  Thus,  inappro-
riate  therapies  equal  or  exceed  appropriate  therapies  in
atients  with  TOF  implanted  in  primary  prevention.
No  relevant  data  are  available  today  on  the  use  of
ubcutaneous  ICDs  in  GUCH  and  hence  in  TOF.  What  is
nown  from  very  limited  early  experience  is  a  high  rate  of
nappropriate  shocks  (issues  in  tachycardia  discrimination
ecause  of  intraventricular  conduction  disturbances  or  T-





igure 1. Anterior (left) and posterior (right) views of repaired tetra
ites of the ventriculotomy/patch at the outflow tract (left) and the ve
otential isthmuses described by Zeppenfeld et al. [55] (see text). RVOTP.  Maury  et  al.
f  anti-brady/tachy  pacing,  which  may  be  relevant  in  TOF
48,49].  An  increased  risk  of  device  exteriorization  and  the
se  of  right  parasternal  screening  have  also  been  evoked
n  GUCH  or  children  implanted  with  a  subcutaneous  ICD
48,50].
Finally,  recent  new  modalities  of  surgical  epicardial  ICD
mplantation  in  congenital  heart  disease  have  been  pro-
osed,  but  with  limited  experience  to  date  [51].
T ablation in TOF
uccessful  catheter  ablation  using  conventional  mapping
echniques,  with  or  without  drugs,  has  been  reported  in
hort  series  of  patients  with  TOF  [52,53],  although  only
imited  success  rates  have  been  reported  in  other  series  [54]
ecause  of  complex  anatomy,  hypertrophied  myocardium,
ense  fibrosis,  broad  isthmuses,  haemodynamic  instability
r  non-inducibility.
Zeppenfeld  et  al.  were  the  first  to  investigate  in  depth
he  details  of  various  VT  reentry  circuits  in  repaired
OF  using  three-dimensional  mapping  [55].  Four  poten-
ial  slow-conducting  VT  isthmuses  were  present  in  most
atients  with  TOF  referred  for  sustained  VT,  and  were
lso  found  in  autopsied  hearts  from  patients  with  TOF
ho  died  shortly  after  surgery:  two  isthmuses  were  bor-
ered  by  the  anterior/lateral  right  ventricular  outflow  tract
RVOT)  scar/patch  and  the  tricuspid  (the  main  one)  or  pul-
onary  annulus  (absent  if  transannular  patch);  while  the
ther  two  were  delineated  by  the  ventricular  septal  defect
car/patch  and  the  tricuspid  (absent  after  closure  of  per-
membranous  septal  defect)  or  pulmonary  annulus  (Fig.  1)
55]. Transecting  anatomic  isthmuses  by  linear  radiofre-
uency  lesions  during  sinus  rhythm  (Fig.  2)  abolished  all
nducible  VT,  and  led  to  a  lack  of  VT  recurrence  in  90%
f  cases  at  30-month  follow-up  [55]. Of  note,  only  half
f  the  patients  were  finally  implanted  with  an  ICD  during
ollow-up.
logy of Fallot right ventricular voltage map, showing scars at the
ntricular septal defect (VSD) patch (right), together with the four
: right ventricular outflow tract.
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Figure 2. Activation during sinus rhythm before (above) and after (below) radiofrequency-induced block of the isthmus located between
tricuspid and pulmonary annulus, with the respective electrograms from both sides of the isthmus. Activation is coded by rainbow colours















block is achieved (below).
All  operated  patients  with  TOF  have  at  least  one  poten-
tial  anatomical  VT  isthmus,  but  isthmuses  were  narrower,
longer  and  had  slower  conduction  in  patients  with  inducible
VT,  according  to  recent  work  from  the  same  group  [56].
Patients  without  a  slow-conducting  isthmus  did  not  present
with  VT  during  follow-up  [56].  This  factor  may  be  pro-
posed  in  the  future  for  stratifying  the  risk  of  late  SCD.
The  same  group  also  demonstrated  that  right-sided  ablation
may  fail  because  of  septal  hypertrophy,  overlying  pulmonary
homograft  or  overlying  ventricular  septal  defect  patch.  In
these  cases,  representing  15%  of  the  patients,  VT  had  to
be  ablated  from  the  left  ventricle  (septum  or  aortic  root)
[57].
Current  guidelines  recommend  a  role  for  ablation  only  as
an  alternative  to  ICD  therapy  in  carefully  selected  patients
with  TOF  (class  I indication)  [1].  Otherwise,  ablation  is  indi-
cated  as  adjunctive  therapy  to  ICD  in  adults  with  TOF  and






owards better prevention of ventricular
rrhythmia
ome  surgical  procedures  may  decrease  late  VT  occurrence.
or  example,  better  cardioprotection  during  extracorporeal
irculation,  shorter  transannular  incisions  or  lack  of  tran-
ection  of  the  annulus,  less  aggressive  muscle  resection  and
ess  generous  RVOT  patching  [58,59]  should  be  preferred
hen  possible.  Earlier  correction  is  probably  worthwhile
ecause  of  less  prolonged  cyanosis,  less  pressure  overload
f  the  right  ventricle,  and  avoidance  of  aortopulmonary
ypass  and  subsequent  less  left  ventricular  volume  over-
oad  [17].  Earlier  correction  of  pulmonary  valve  stenosis
r  regurgitation  by  surgical  or  even  percutaneous  interven-
ion  [60]  is  probably  also  beneficial,  even  if  still  unproved.
ubpulmonary  resection  and  ventricular  septal  defect  clo-
ure  can  be  accomplished  transatrially,  while  pulmonary
alve/artery  surgery  can  be  achieved  through  a  pulmonary












































hich  will  probably  carry  a  reduced  arrhythmia  risk  in  the
ong  term  [63],  despite  experience  still  being  lacking.
Finally,  surgical  ablation  guided  by  electrophysiological
apping  performed  during  or  before  surgery  may  be  con-
idered  in  TOF  with  inducible  sustained  monomorphic  VT
ith  an  identified  critical  isthmus  (class  IIb  indication)  [24].
tudies  are  still  pending,  however,  for  the  evaluation  of  the
linical  role  of  this  dual  strategy  in  decreasing  late  SCD
ccurrence.
onclusions
alignant  ventricular  arrhythmias  and  SCD  probably  occur
ess  frequently  than  previously  thought  in  repaired  TOF,  and
ill  possibly  become  even  less  common  with  the  advent
f  new  surgical  techniques/management.  There  are  cur-
ently  no  recommended  indications  for  prophylactic  ICDs
except  perhaps  in  very  selected  cases  based  on  multiple
isk  factors),  while  radiofrequency  ablation  may  be  proposed
n  secondary  prevention,  with  or  even  without  a  back-up
CD  in  selected  cases.  Repeated  cardiological  investiga-
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